Liver X receptors in cardiac hypertrophy:New insights into metabolic remodeling by Cannon, Megan Valerie
  
 University of Groningen
Liver X receptors in cardiac hypertrophy
Cannon, Megan Valerie
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Cannon, M. V. (2015). Liver X receptors in cardiac hypertrophy: New insights into metabolic remodeling.
[Groningen]: University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Chapter 3
Cardiac LXRα protects against pathological cardiac 
hypertrophy and dysfunction 
by enhancing glucose uptake and utilization
Megan V. Cannon1, Herman H.W. Silljé1, Jürgen W.A. Sijbesma2, Inge Vreeswijk-Baudoin1, 
Jolita Ciapaite3, Bart van der Sluis4, Jan van Deursen5, Gustavo J.J. Silva6, Leon J. de Windt6, 
Jan-Åke Gustafsson7,8, Pim van der Harst1, Wiek H. van Gilst1, Rudolf A. de Boer1
1 University Medical Center Groningen, University of Groningen, Department of Cardiology 
2 University Medical Center Groningen, University of Groningen, Department of Nuclear Medicine
3 University Medical Center Groningen, University of Groningen, Department Pediatrics, Center for Liver, 
Digestive and Metabolic Diseases 
4 University Medical Center Groningen, University of Groningen, Department of Pathology and Medical Biology, 
5 Department of Biochemistry & Molecular Biology, Mayo Clinic
6 Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University




LXRα protects the heart by glucose regulationChapter 3
ABSTRACT
Background. Pathological cardiac hypertrophy is characterized by a shift in metabolic 
substrate utilization from fatty acids to glucose, but the molecular events underlying the 
metabolic remodeling remain poorly understood. Here, we investigated the role of liver 
X receptors (LXRs), which are key regulators of glucose and lipid metabolism, in cardiac 
hypertrophic pathogenesis. 
Methods and results.  Using a transgenic approach in mice, we show that overexpression 
of LXRα acts to protect the heart against hypertrophy, fibrosis, and dysfunction. Gene 
expression profiling studies revealed that genes regulating metabolic pathways were 
differentially expressed in hearts with elevated LXRα. Functionally, LXRα overexpression in 
isolated cardiomyocytes and murine hearts markedly enhanced the capacity for myocardial 
glucose uptake following hypertrophic stress. Conversely, this adaptive response was 
diminished in LXRα-deficient mice. Transcriptional changes induced by LXRα overexpression 
promoted energy-independent utilization of glucose via the hexosamine biosynthesis 
pathway, resulting in O-GlcNAc modification of GATA4 and Mef2c and the induction of 
cytoprotective natriuretic peptide expression. 
Conclusion.  Our results identify LXRα as a key cardiac transcriptional regulator that helps 
orchestrate an adaptive metabolic response to chronic cardiac stress, and suggests that 
modulating LXRα may provide a unique opportunity for intervening in myocyte metabolism.
51
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INTRODUCTION
Pathological cardiac hypertrophy and remodeling ensue in response to sustained elevations 
in hemodynamic workload (1). A hallmark of this remodeling process is the alteration in 
myocardial energy metabolism which is necessitated by increased energy demand (2,3). 
Under normal physiological conditions, the heart predominantly consumes fatty acids 
(FA), whereas various stressors trigger a compensatory shift toward glucose, the preferred 
substrate for its oxygen-sparing effect in ATP production (4,5). Despite the success of current 
pharmacological strategies which aim to reduce afterload and hypertrophic growth using 
beta blockers and inhibitors of the renin-angiotensin-aldosterone system, heart failure 
nevertheless remains a progressive disease with high morbidity and mortality. Interventions 
in metabolic remodeling therefore represent a promising therapeutic adjunctive for 
targeting pathological cardiac hypertrophy and development of heart failure (6).
Liver X receptors (LXRs) are nuclear receptors that have emerged as central metabolic 
regulators in various organ systems and cell types. At the molecular level, LXRs function as 
ligand-activated transcription factors that intricately regulate and coordinate cholesterol 
homeostasis, glucose and lipid metabolism, and inflammatory signaling. Inasmuch, the 
importance of LXRs in the cardiovascular system is mainly attributed to their atheroprotective 
effects in accelerating reverse cholesterol transport (7,8), and reducing atherosclerotic 
lesion size and inflammation (9-11). The biological functions of LXRs are mediated via 
two subtypes, LXRα (NR1H3) which is predominantly expressed in liver, adipose, intestine, 
and macrophages, but also in heart, kidney, adrenal gland, and lung, and LXRβ (NR1H2), 
expressed ubiquitously (12). LXRs reside in the nucleus where they heterodimerize with 
retinoid X receptor and are bound to cognate LXR response elements (LXREs) in regulatory 
regions of target genes (13). 
Less is known regarding the role of LXR in pathological cardiac hypertrophy. LXRs have been 
implicated in blood pressure control by regulating renin gene expression in vivo (14). In 
blood pressure-independent models, the LXR agonist, T0901317 (T09), attenuated the 
hypertrophic response to pressure overload in mice (15), whereas this effect was exacerbated 
in LXRα-null mice (16). These studies, however, are limited by confounding systemic effects 
of pharmacological LXR activation and by the lack of agonist specificity. Therefore, it remains 
unclear whether LXRα directly affects the pathogenesis of hypertrophy. The purpose of the 
present study was to investigate the cardiospecificity of LXRα in modulation of myocardial 
metabolism and pathological hypertrophy by generating a murine model of cardiac-specific 
LXRα overexpression.
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METHODS
An expanded Methods section is provided in the Data Supplement.
Animal models
The murine NR1H3 gene (GeneBank: NM_013839) was obtained from German Science 
Centre for Genomic Research (RZPD; clone # IRAVp968B0923D). This PCR product was 
amplified by polymerase chain reaction (PCR) and cloned into a previously described 
vector containing the cardiac-specific αMHC promoter (53). Transgenic founders were 
obtained by pronuclear injection of the αMHC-LXRα construct into FVB oocytes. Transgene 
identification was performed by a PCR-based method using the following primers: sense 
5’- CGGCACTCTTAGCAAACCTC-3’, antisense 5’-TGCTGACTCCAACCCTATCC-3’. Mice were 
backcrossed for at least three generations into the C57BL/6 (#000664, The Jackson 
Laboratory) genetic background. αMHC-LXRα (LXRα-Tg) mice were generated by the UMCG 
mouse clinic in collaboration with the Mayo Clinic (Rochester, NY, USA). For all experiments, 
non-transgenic littermates (Wt) served as controls. Homozygous LXRα knockout mice (LXRα-
/-; gift from Dr. Gustafsson) (54) and matching C57BL/6BomTac wild-type (WT) mice were 
obtained from Taconic, Denmark. 
Experimental protocol
All experimental protocols were approved by the Institutional Animal Care and Use 
Committee at the University of Groningen. Male mice (8-10 weeks) were subjected to an 
infusion of angiotensin II (Ang II) (1.0 mg/kg/day) for 10 days, or pressure overload by 
transverse aortic constriction (TAC) for either 1 or 5 weeks. In subsequent studies, a subset 
of mice underwent sham/TAC for 5 weeks for further assessment of myocardial 2-deoxy-
2-(18F)fluoro-D-glucose (FDG)-glucose uptake with microPET, or mitochondrial oxidative 
phosphorylation measurements. Cardiac function was determined with echocardiography 
and invasive hemodynamic monitoring, as previously described (55). LV tissue samples were 
used to perform expressional studies, immunohistochemical, and biochemical analyses. 
In vitro studies
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1-3 day old Sprague-
Dawley pups, as described (56). Recombinant adenovirus containing murine LXRα (Ad-
LXRα) or silenced LXRα (si-LXRα) was used to infect NRVMs, and cells were treated with 
phenylephrine (PE), or 6-diazo-5-oxonorleucine (DON) (Sigma). Cellular glucose uptake 
and protein synthesis were assessed with 2-deoxyglucose (2-DG) and [3H]leucine assays, 
respectively.
Statistical analysis
All data are presented as means ± standard error of the mean (SEM). Student’s paired 
2-tailed t-test was used for two group comparisons. One-way ANOVA was performed to 
analyze differences for multiple-group comparisons, followed by Bonferroni post hoc 
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analysis. Kruskall-Wallis test followed by Mann-Whitney U test was used to analyze cell 
experiments. All results were tested at the P<0.05 level of significance. 
RESULTS
Mice with cardiac-specific LXRα overexpression exhibit no overt cardiac 
phenotype at baseline or with aging
To study LXRα activation in the heart, we generated transgenic (LXRα-Tg) mice with 
cardiac-specific overexpression of murine LXRα driven by the cardiomyocyte-specific 
αMHC promoter (Figure 1A). LXRα mRNA and protein expression were increased 130-
fold and 9-fold, respectively (Figure 1B, 1C and 1D). Heart weight in LXRα-Tg mice, as 
Figure 1
Baseline characterization of mice with cardiac-specific LXRα overexpression. (A) Murine LXRα DNA construct for 
the generation of transgenic (LXRα-Tg) mice. (B-D) Left ventricular LXRα expression in Wt and LXRα-Tg mice aged 
12 wks. (B) Western blot of LXRα in liver and LV tissue. Quantification of (C) mRNA expression (normalized to 
36b4; n=6-8/group), and (D) protein expression (normalized to GAPDH; n=4/group). (E) LV weight to tibia length 
ratios (LV/tibia); n=15/group. (F) Assessment of mean arterial pressure (MAP) with in situ catheterization. (G) 
Representative Massons trichrome and wheat germ agglutinin (WGA)-FITC staining in cross-sectional LV, bars = 100 
µm, 10 µm. (H) Relative mRNA levels of known LXRα-associated and target genes; n=7-8/group. Data are means ± 
SEM; *P<0.05, ***P<0.001 versus Wt.
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assessed by LV weight normalized to tibia length (LV/tibia), was marginally less compared 
to Wt (Figure 1E). Mean arterial pressure (MAP) was unaltered in LXRα-Tg mice (Figure 
1F). Echocardiography-determined LV dimensions and function were comparable to Wt, and 
no differences in indices of contractility and intracardiac pressures, measured in situ with 
microtip catheterization, were observed (Suppl. Table 1). Histological analyses of ventricular 
sections stained with WGA-FITC or Massons trichrome displayed no evidence of abnormal 
cardiomyocyte morphology or collagen deposition in LXRα-Tg hearts (Figure 1G). To verify 
whether overexpression indeed induced functionally active LXRα, we determined mRNA 
levels of well described LXRα target genes (17) including Srebp1c, Scd1, and Abca1. These 
were significantly increased in LXRα-Tg mice (Figure 1H). Furthermore, Pgc1a, a co-activator 
Figure 2
LXRα overexpression attenuates TAC-induced cardiac hypertrophy and fibrosis after 5 weeks. (A) LV/tibia ratios in 
sham- and TAC-operated Wt and LXRα-Tg mice; n=21-26/group. (B) Quantification of cardiomyocyte cross-sectional 
area from WGA-FITC stained histological sections; n=3-5/group. (C) Representative LV sections stained with WGA-
FITC and Massons trichrome to assess cardiomyocyte hypertrophy and fibrosis, respectively; bars = 1 mm, 100 µm, 
10 µm. (D) Whole area percentage of fibrosis in Massons trichrome stained sections. (E) Measurement of mRNA 
levels to assess induction of fetal gene program, as well as hypertrophy (Rcan1) and fibrosis (Col1a1, Ctgf). Data 
are means ± SEM; n=7-8/group unless indicated; *P<0.05, **P<0.01, ***P<0.001 versus respective sham, #P<0.05, 
##P<0.01, ###P<0.001 versus Wt.
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of LXR (18), was also upregulated, plausibly to maintain LXRα in a constitutively active state. 
Lxrb expression was not changed. The long-term effects of cardiac-specific LXRα activation 
were also assessed in mice up to 12 months of age. Chronic LXRα activation did not impair 
gross cardiac morphology or function in aged mice (Suppl. Table 1). In summary, LXRα-Tg 
mice displayed normal physiological development, and all structural and functional cardiac 
parameters were within normal range.
LXRα overexpression attenuates pathological development of cardiac 
hypertrophy, fibrosis, and dysfunction
To evaluate specific effects of LXRα in pathological cardiac hypertrophy, mice were 
subjected to pressure overload by TAC for 5 weeks. Heart weights were similar between 
sham-operated Wt and LXRα-Tg groups (Figure 2A). TAC caused significant increases in LV/
tibia ratios, however, LXRα-Tg mice exhibited 24% less hypertrophy compared to Wt, which 
was further evidenced by reduced cardiomyocyte size (Figure 2B and 2C). In comparison to 
LXRα-Tg mice, the greater degree of hypertrophy observed in Wt was attributable to larger 
increases in interventricular septal and LV free wall thicknesses, while no marked dilatation 
of the LV chamber was observed for either TAC group (Suppl. Table 2). To further assess 
Figure 3
Reduced cardiac dysfunction in mice with cardiac LXRα activation in response to pathological pressure overload. 
(A) Echocardiographic assessment of percent fractional shortening in mice subjected to 5 weeks of TAC; n=19-26/
group. (B-D) Hemodynamic measurements obtained in situ in sham- and TAC-operated mice; n=6-8/group. (B) 
Mean arterial pressure (MAP), (C) LV end-systolic pressure (LVESP), and (D) LV end-diastolic pressure (LVEDP). 
Data are means ± SEM; *P<0.05, ***P<0.001 versus respective sham, ##P<0.01 versus Wt.
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the impact of LXRα on other parameters of myocardial remodeling, fibrosis was quantified 
in cross-sectional LV. Collagen deposition was only marginally detected in LXRα-Tg hearts 
following TAC, whereas this increased 4-fold in Wt (Figure 2C and 2D). These anti-fibrotic 
effects were associated with less induction of genes involved in fibrogenesis, Col1a1 and 
Ctgf (Figure 2E). Following TAC, typical reactivation of the fetal gene program occurred in 
both groups, but to a lesser extent in LXRα-Tg mice (Figure 2E). Interestingly, we observed 
elevated basal levels of natriuretic peptides, Anp and Bnp, in LXRα-Tg mice. In contrast, 
other gene markers representative of fetal gene activation were more strongly induced in 
Wt following TAC: αMHC to βMHC isoform transition (Myh6/Myh7 ratio), Acta1, as well as 
the hypertrophic gene, Rcan1.
Functional evaluation revealed that Wt mice subjected to TAC achieved significantly less 
systolic LV thickening and demonstrated greater acceleration toward heart failure as 
fractional shortening declined 11% versus only 6% in LXRα-Tg (Figure 3A). These functional 
improvements in LXRα-Tg mice were further accompanied by reduced intracardiac pressures 
(Figure 3C and 3D). No changes in MAP or HR were recorded (Figure 3B, Suppl. Table 2). 
To determine whether cardiac LXRα overexpression affects early hypertrophic remodeling 
processes, mice were subjected to 1 week of TAC-induced pressure overload. Cardiac 
hypertrophy was present in Wt mice after 1 week of TAC, however, this was significantly 
attenuated in LXRα-Tg mice (Suppl. Fig. 1A). Assessment of cardiac function with 
echocardiography indicated that function remained relatively compensated in TAC-operated 
mice (Suppl. Fig. 1B). The effect of cardiac LXRα on hypertrophy, including expression of fetal 
genes (Suppl. Fig. 1C), are comparable to what we observed after 5 weeks TAC. Molecular 
determinants of inflammation were more strongly upregulated in Wt hearts compared to 
LXRα-Tg (Suppl. Fig. 1D-G), whereas the anti-apoptotic factor, Bcl2, was significantly induced 
with LXRα overexpression (Suppl. Fig. 1I and 1J). These data implicate an anti-inflammatory 
role for LXRα in the initial phase of hypertrophic pathogenesis, and possible protection 
against anti-apoptotic triggers.
To further verify that our observations were not model-dependent, we conducted 
experiments with Ang II infusion over 10 days. Consistent with our findings from TAC 
experiments, LXRα-Tg mice showed reduced Ang II-induced myocardial hypertrophy and 
fibrosis with moderate improvements in hemodynamic parameters (Suppl. Fig. 2). Taken 
together, these data demonstrate that cardiac-specific LXRα activation ameliorates adverse 
cardiac remodeling and dysfunction in mice in response to diverse pathological hypertrophic 
stimuli.
LXRα overexpression induces transcriptional alterations in metabolic pathways
Gene profiling of the LV transcriptome was performed to uncover the molecular basis for 
the cardioprotective phenotype observed in LXRα-Tg mice (Suppl. Fig. 3, Suppl. Table 3). 
Basal LXRα overexpression induced substantial changes in genes relating to metabolism 
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(Figure 4A). To further investigate microarray pathway analysis, mRNA levels of several key 
genes regulating FA and glucose metabolism were determined (Suppl. Fig. 4). In LXRα-Tg 
hearts, glycolysis-related genes were more differentially expressed, including upregulation 
of the glucose transporters, Glut1 and Glut4, as well as Pdk4, regulating pyruvate oxidation 
in mitochondria. 
TAC provoked parallel transcriptional alterations in Wt and LXRα-Tg mice, downregulating FA 
metabolism and similarly upregulating pathways pertaining to extracellular remodeling and 
cardiovascular disease. However, the comparison between differentially expressed genes 
in hypertrophic hearts was most striking for LXRα-Tg where more than 50% of upregulated 
genes clustered into metabolic pathways, for example glutathione metabolism. Collectively, 
these expression data convey that LXRα activation transcriptionally reprograms metabolic 
pathways in the heart, specifically glucose metabolism. 
Figure 4
Cardiac LXRα overexpression enhances myocardial glucose uptake. (A) Classification of genes differentially 
expressed in LXRα-Tg hearts (see Supplemental Figure 3). (B) Representative 18F-FDG images with microPET. (C) 
Myocardial FDG uptake measured as standard uptake value (SUV) in Wt and LXRα-Tg mice 5 weeks post TAC; n=4-
6/group. (D) Quantification of myocardial glycogen content; n=5-7/group. (E) GLUT protein expression in LV tissue 
normalized to GAPDH; n=5-7/group. Data are means ± SEM; *P<0.05 versus respective sham, #P<0.05, ##P<0.01 
versus Wt.
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Constitutive LXRα activation enhances myocardial glucose uptake and utilization 
We next evaluated whether global transcriptional changes relating to glucose metabolism 
translated into a functional metabolic outcome. To this end, in vivo glucose uptake 
measurements were performed in a separate sham/TAC cohort (n=22) by injecting mice 
Figure 5
LXRα-null mice manifest reduced myocardial glucose uptake capacity in response to TAC. (A) LV/tibia ratios in 
sham- and TAC-operated WT and LXRα-/- mice; n=8-12/group. Cardiac functional assessment at 5 weeks post TAC, 
(B) percent fractional shortening determined with echocardiography (§ P=0.06), and (C) LV end-diastolic pressure 
(LVEDP) recorded in situ; n=7-12/group. (D-G) Relative mRNA gene expression, normalized to 36b4; n=8. (H) 
Western blot detection of GLUT protein expression in LV tissue normalized to GAPDH, expressed as fold change; 
n=6-8/group. (I) Representative 18F-FDG microPET scans. (J) Myocardial FDG uptake quantified as standard uptake 
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with FDG and using microPET imaging modality. Basal myocardial FDG-glucose uptake was 
1.9-fold higher in LXRα-Tg mice compared to Wt, indicating a greater propensity for glucose 
utilization. Consistent with previous reports showing a substrate shift to glucose following 
hypertrophic perturbation (19,20), TAC lead to a substantial increase in FDG-glucose uptake 
in both groups. Wt mice achieved 90% increase, which subsequently matched basal LXRα-Tg 
levels. On the other hand, TAC-operated LXRα-Tg mice exhibited comparatively even greater 
capacity for glucose uptake that was augmented 50% above both basal LXRα-Tg levels and 
that of Wt TAC cohorts (Figure 4B and 4C). Increased glucose uptake in LXRα-Tg hearts did 
not impact systemic blood glucose levels as no significant differences in basal levels prior to 
scan, nor under fasted conditions (Supp. Table 1) were observed. Furthermore, enhanced 
glucose uptake was not stored, but rather utilized since myocardial glycogen content was 
unaltered (Figure 4D). 
Expression levels of several key proteins involved in substrate metabolism and regulation 
were measured. In concert with FDG-glucose uptake levels, GLUT1 and GLUT4 protein levels 
were increased in LXRα-Tg hearts (Figure 4E), suggesting their membrane translocation 
and functionality. No appreciable differences between LXRα-Tg and Wt were observed for 
hexokinase 2 (HK2), the enzyme catalyzing the first step in glycolysis, nor phosphorylated-
AMPK, a key metabolic regulator in response to increased workload and energetic stress, 
as well as for CD36 regulating myocardial FA uptake (Suppl. Fig. 5). In summary, enhanced 
myocardial glucose uptake evidenced in LXRα-Tg mice in the stressed and non-stressed 
state is associated with induction of GLUT1 and GLUT4.
LXRα-deficient mice manifest reduced myocardial glucose uptake capacity in 
response to TAC
To gain further insight into LXRα regulation of myocardial metabolism in cardiac hypertrophy, 
loss-of-function studies were performed in LXRα-/- mice. Following 5 weeks of pressure 
overload, both WT and LXRα-/- mice developed LV hypertrophy (Figure 5A). The relative 
increases in LV/tibia ratios were considerably higher for LXRα-/- compared to WT, 50% versus 
30%, albeit not significantly different from each other. Furthermore, LXRα-deficient hearts 
exhibited a greater tendency toward cardiac dysfunction (Figure 5B and 5C). Activation of 
the fetal gene program occurred to a similar extent in both LXRα-/- and WT mice (Figure 
5D-G). 
The metabolic response of LXRα-null hearts to hypertrophic perturbation was assessed by 
evaluating myocardial glucose uptake and GLUT expression. Both GLUT1 and GLUT4 were 
evidently less upregulated in LXRα-/- hearts in response to TAC (Figure 5H). Furthermore, 
FDG-glucose analysis with microPET revealed that LXRα-/- mice demonstrated an inability 
to normalize the increases in glucose uptake levels achieved in pressure overload-induced 
hypertrophy (Figure 5I and 5J, Suppl. Fig. 6). Myocardial glucose uptake increased 1.6-fold 
in WT, but only 1.3-fold in LXRα-/- mice. Overall, loss of LXRα resulted in a more progressive 
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deterioration of function following TAC that was associated with a compromised adaptive 
capacity to augment glucose uptake.
Mitochondrial oxidative capacity of pyruvate is unaltered by chronic LXRα 
overexpression
To assess whether LXRα-Tg mice displayed increased mitochondrial capacity to oxidize 
glucose-derived substrates, we determined oxidative phosphorylation in permeabilized LV 
muscle fibers in the presence of pyruvate in an additional sham/TAC cohort (n=26). Basal 
Figure 6
LXRα enhances glucose uptake and O-GlcNAc signaling via the hexosamine biosynthetic pathway (HBP) in 
cultured cardiomyocytes. Neonatal rat ventricular myocytes were transfected with Ad-LXRα or GL2 (Ad-cont), and 
treatments with phenylephrine (PE) and DON (inhibitor of HBP) were initiated for 24 hours. (A) Assessment of 
2-deoxyglucose (2-DG) uptake. (B-C) Glut mRNA expression. (D) Western blot indicating Ad-LXRα- and PE-induced 
increases in global protein O-GlcNAcylation, which was abrogated following inhibition of HBP with DON. LXRα 
protein expression is shown, and GAPDH served as loading control. (E-F) Modulation of Anp and Bnp mRNA levels 
by Ad-LXRα-induced O-GlcNAc signaling. (G) Measurement of cell size. (H) Representative images for determination 
of cell size. Cells were stained with an antibody specific for LXRα (green, indicated by arrow), DAPI for nuclei (blue), 
and rhodamine-phalloidin for F-actin (red); bar = 50 µm. All cell experiments were repeated 4-5 times and data are 
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(state 2) and maximal ADP-stimulated (state 3) oxygen consumption rates did not differ 
among stressed and unstressed LXRα-Tg and Wt hearts (Suppl. Fig. 7A), indicating that the 
capacity for pyruvate oxidation was neither impaired nor enhanced by LXRα overexpression 
or by TAC. Citrate synthase activity, a marker of mitochondrial density and to which all 
respirometry measurements were normalized, was similar for all groups (Suppl. Fig. 7B).
Interestingly, we recorded increased state 2 and 3 respiration rates with parmitoyl (C16)-
carnitine in LXRα-Tg, suggesting a trend toward increased capacity to oxidize FA (Suppl. Fig. 
7C). This may be due to a reciprocal effect on pyruvate oxidation by Pdk4, which was induced 
in LXRα-Tg (Suppl. Fig. 4A). The respiratory control ratio, indicative of overall mitochondrial 
function (21), tended to be higher for parmitoyl-carnitine in stressed and unstressed hearts 
overexpressing LXRα (Suppl. Fig. 7D). Further lipid profiling revealed increased myocardial 
leanness in LXRα-Tg hearts (Suppl. Fig. 8), despite induction of several lipogenic gene targets 
(Srebp1c, Scd1, Fasn) (Figure 1H, Suppl. Fig. 4B). 
LXRα-mediated glucose uptake increases O-GlcNAc signaling in cardiomyocytes 
Since no differences in mitochondrial capacity to utilize pyruvate was identified, we 
postulated that beneficial effects derived from LXRα-mediated enhanced glucose 
uptake involved alternate pathways of glycolytic metabolism. One such pathway is the 
hexosamine biosynthesis pathway (HBP) which culminates in the formation of O-GlcNAc, 
Figure 7 
Knockdown of LXRα increases cellular hypertrophy in cultured cardiomyocytes. Cells were transfected with Ad-
LXRα, si-LXRα or Ad-cont, in the absence of presence of phenylephrine (PE). (A) Protein synthesis determined via 
leucine incorporation. (B) O-GlcNAc protein expression on Western blot. (C-F) mRNA expression, normalized to 
36b4. All cell experiments were repeated 4-5 times and data are reported as fold change with respect to control 
group. Data are means ± SEM; *P<0.05, **P<0.01, §P=0.06 versus Ad-cont, #P<0.05, ##P<0.01.
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a posttranslational modifier of numerous proteins. The HBP has been demonstrated to be 
an essential signaling system in the failing heart (22), and accumulating evidence from in 
vitro and ex vivo systems shows that augmented O-GlcNAc levels via the HBP potentiates 
cytoprotection (23,24). Using NRVMs, we tested the hypothesis that LXRα-mediated 
increases in glucose uptake would enhance substrate availability for O-GlcNAc. NRVMs 
transfected with Ad-LXRα showed significantly elevated 2-deoxyglucose (2-DG) levels of 1.8-
fold compared to Ad-cont cells, which was further augmented 40% following PE stimulation 
(Figure 6A). Glut4 and Glut1 mRNA were correspondingly increased (Figure 6B and 6C). Next, 
we assessed whether enhanced glucose availability led to HBP activation and downstream 
formation of O-GlcNAc. Ad-LXRα cells displayed increased global protein O-GlcNAcylation 
that was further enhanced with PE (Figure 6D). Administration of DON to inhibit HBP flux 
attenuated Ad-LXRα-increased O-GlcNAcylation (Figure 6D), confirming the link between 
LXRα and HBP-O-GlcNAc signaling.
From our findings in LXRα-Tg mice, we speculated that increased myocardial natriuretic 
peptide expression (Figure 2E) in conjunction with preference for glucose may, in part, be 
Figure 8
O-GlcNAcylation is increased with cardiac LXRα overexpression in mice. (A-B) Western blot analyses of global 
protein O-GlcNAc levels in left ventricles of mice with either (A) cardiac-specific LXRα overexpression, or (B) LXRα 
deficiency, and subjected to 5 weeks TAC. (C-D) Nuclear protein extracts were precipitated with agarose WGA in the 
absence or presence of GlcNAc, a competitor, and analyzed by Western blot with antibodies against Mef2c, GATA4, 
or Nkx-2.5, known transcription factors of natriuretic peptides; bands represent 3 pooled hearts per Wt and LXRα-
Tg lanes, and (D) quantification is for n=2, expressed as fold change. IP, immunoprecipitation; WGA, wheat germ 
agglutinin; GlcNAc, N-acetylglucosamine; WB, Western blot. Data are means ± SEM.
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evidence of an endogenous cardioprotective stress response elicited via LXRα overexpression. 
The anti-hypertrophic properties of ANP and BNP are well established (25). Ad-LXRα cells 
expressed both increased Anp and Bnp (3.2-fold and 3.8-fold, respectively), which were 
subsequently suppressed following DON inhibition, suggesting that their induction is linked 
to O-GlcNAc effector signaling (Figure 6E and 6F). Further assessment of cellular hypertrophy 
indicated that DON inhibition of HBP flux also abolished the Ad-LXRα-mediated reductions 
in cell size that was increased upon PE stimulation (Figure 6G and 6H).
Alternative experiments were performed with si-LXRα to address the causal relationship 
among LXRα expression, protein O-GlcNAc modification, and hypertrophy. Knockdown of 
LXRα led to comparatively higher levels of hypertrophic growth (Figure 7A), and lower levels 
of O-GlcNAc following PE-induced cellular stress (Figure 7B). Interestingly, gene expression 
analysis (Figure 7C-F) revealed significant downregulation of Anp in LXRα-silenced cells 
(Figure 7C). 
Transcriptional activators of natriuretic peptides are O-GlcNAc modified in LXRα-
Tg hearts
Finally, to corroborate our in vitro findings, we assessed global protein O-GlcNAc levels 
from LV tissue lysates of mice overexpressing and deficient for LXRα. Most extensive 
O-GlcNAcylation was observed in LXRα-Tg hearts involving proteins between 40 and 55 kDa 
in size (marked in Figure 8A). In contrast, loss of LXRα resulted in attenuated O-GlcNAc 
signal in response to TAC (Figure 8B). To further identify specific O-GlcNAc targets, agarose 
Figure 9
Schematic representation of LXRα-mediated glucose protection.  
LXRα transcriptionally regulates glycolytic metabolism by targeting glucose utilization at distinct levels. Increased 
Glut1 and Glut4 enhance glucose uptake, and Pdk4 regulates pyruvate oxidation in mitochondria. Subsequent 
increases in glycolytic flux activate the HBP, resulting in downstream O-GlcNAc modification of transcription factors 
inducing natriuretic peptide expression, a putative end effector mediating anti-hypertrophic effects in the heart. 
ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; F-6-P, fructose-6-phosphate; Glut, glucose 
transporter; HBP, hexosamine biosynthesis pathway; Mef2c, myocyte enhancer factor 2C; O-GlcNAc, β-O-linkage of 
N-acetylglucosamine; PDC, pyruvate dehydrogenase complex; Pdk4, pyruvate dehydrogenase kinase 4.
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wheat germ agglutinin (WGA) precipitation was performed to isolate nuclear GlcNAcylated 
proteins. Using antibodies specific for known transcription factors activating ANP and BNP 
(26,27), Western blot analysis revealed that GATA4 and Mef2c precipitated with WGA in 
LXRα-Tg hearts, but not with Nkx-2.5, suggesting that O-GlcNAc modification of GATA4 
and Mef2c potentiate their activities (Figure 8C and 8D). N-acetylglucosamine (GlcNAc), a 
competitor, served as control.
In summary, these data indicate that cardiac LXRα integrates glucose metabolism and 
downstream O-GlcNAcylation with induction of cytoprotective natriuretic peptides to 
orchestrate an anti-hypertrophic response. Therefore, the energy-independent effects of 
glucose that, herein, are governed by LXRα may be an important salutary mechanism in 
modulating and preserving myocyte function (Figure 9).
DISCUSSION
In the present study, we describe a cardiac-specific overexpression model for LXRα in mice, 
and herewith, elucidate the significance of LXRα in modulating myocardial metabolism 
in pathological hypertrophy. We established that constitutive LXRα activation in murine 
hearts substantially diminished LV hypertrophy, adverse cardiac remodeling, and improved 
overall cardiac function following chronic pressure overload and Ang II stimulation. Using 
this model, we identified the intrinsic transcriptional regulatory mechanisms LXRα exerts 
in the heart and in counteracting hypertrophic stress. By principally modulating glucose 
pathways, LXRα functionally enhanced the capacity for myocardial glucose uptake, which 
was conversely impaired in hypertrophic hearts deficient for LXRα. Furthermore, increased 
glucose utilization via an energy-independent pathway resulted in the glycosylation of 
transcription factors inducing natriuretic peptide expression, which we identified as a 
putative end effector of LXRα-mediated protective effects in the heart. 
The role of LXRα in protection against cardiac pathophysiology is not well established. This 
has been previously addressed in pharmacological studies using the LXR agonist, T09, and 
LXRα-null mice (15,16). Conceivably, these approaches are restrained by confounding 
variables associated with systemic LXR activation, which include lipogenic (13), anti-
inflammatory (28), and blood pressure lowering (29) effects. Moreover, T09 mediates its 
effects indiscriminately via other nuclear receptors since it is also a co-activator of farnesoid 
X receptor, pregnane X receptor, and retinoic acid receptor signaling (30-32). Selectively 
overexpressing cardiac LXRα in mice circumvented these confounding factors and afforded 
a system for delineating the heart-specific effects of LXRα. Using two diverse hypertrophic 
perturbations, we demonstrated that constitutive LXRα activation countervailed pathological 
growth and remodeling processes in the heart, including blunting the development 
of myocardial fibrosis, an observation in line with previous studies demonstrating the 
anti-fibrotic effects of LXRs in kidney (33) and in liver (34). Cardiac LXRα also appears to 
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influence early remodeling processes since less inflammation in association with decreased 
hypertrophy occurred at an earlier time point of 1 week post TAC. LXRα-Tg mice  may also be 
less susceptible to apoptosis, which is underscored by upregulation of Bcl2. Taken together, 
counteraction of inflammatory signaling and myocyte death may explain the attenuated 
development of fibrosis remodeling we observed after 5 weeks TAC.
In loss-of-function studies, LXRα-/- mice did not develop significantly greater severity of 
hypertrophy with respect to WT, although function was worsened in LXRα-deficient hearts. 
This is in contrast to a previous report showing exacerbated hypertrophic response in LXRα-
/- mice (16). The discrepancy between LXRα overexpression and deficiency cannot be fully 
explained herein, however, our in vitro data indicate that, at the cellular level, there is a 
clear effect on hypertrophic growth in cardiomyocytes lacking LXRα, and thus compensatory 
mechanisms may be operative in the intact heart. Interestingly, recent evidence from a 
genome-wide association study (GWAS) of electrocardiographic LV hypertrophy (LVH) found 
a genetic variant, or SNP, in the LXRα (Nr1h3) locus to be significantly associated with the 
LVH trait. Furthermore, expression QTL analysis showed a significant correlation between 
decreased expression of Nr1h3 and increased LVH, Van der Harst, unpublished data, [2011], 
supporting an anti-hypertrophic role for LXRα. 
Functionally, gene profiling in our model of cardiac-specific LXRα overexpression identified 
primary effects for LXRα on metabolic pathways, and further investigation into this metabolic 
profile revealed that myocardial glucose uptake in association with GLUT expression was 
significantly increased in LXRα-Tg hearts and in isolated cardiomyocytes. GLUT1 and GLUT4 
have previously been elucidated as targets for transcriptional regulation by LXRs in adipose 
tissue and skeletal muscle (35-39). Myocardial glucose uptake capacity was enhanced in 
LXRα-Tg mice, and more importantly, when challenged with hypertrophic stress, these mice 
demonstrated an even more robust response versus that of Wt. Conversely, insufficient 
glucose uptake capacity that ensued in hypertrophic hearts deficient for LXRα resulted in 
a worsened functional outcome. The shift toward greater glucose reliance is believed to 
be an adaptive response that confers cardioprotection (4,40), and evidence from other 
genetic mouse models renders further support for a role for glucose uptake in myocardial 
protection. Cardiac-specific overexpression of GLUT1 in mice increased glucose uptake 
and glycolysis which prevented the development of ventricular dysfunction and improved 
survival (19,41), whereas reduced glucose utilization in GLUT4 knockout mice manifested 
greater hypertrophy and acceleration toward heart failure (42,43). With cardiac insulin 
resistance and metabolic dysregulation known to precede the development of heart failure 
(44,45), strategies sensitizing the heart to glucose uptake may thus have clinically relevant 
implications in the long-term prognosis of heart failure. 
Since glucose uptake rates were enhanced by LXRα activation, we hypothesized that this 
would also lead to downstream changes in energy-dependent pathways, causing increased 
mitochondrial oxidative capacity. However, we did not observe corresponding increases in 
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oxidative capacity from pyruvate, suggesting that LXRα does not transcriptionally reprogram 
pathways for enhancement of mitochondrial glucose utilization. In essence, glucose uptake 
and glycolysis appears to be partially uncoupled from mitochondrial oxidation and ATP 
synthesis in LXRα-Tg hearts, possibly via a regulatory effect of LXRα on Pdk4, which negatively 
regulates pyruvate dehydrogenase complex (PDC) activity. This is in contrast to previous 
reports showing that, in the protection against cardiac stress, GLUT1 overexpression 
corrected insufficient glucose utilization and oxidation caused by PPARα deficiency in mice 
(41), and preserved mitochondrial energetic status (19). That glucose oxidative capacity is 
not increased in LXRα-Tg hearts may be due to the fact that mitochondrial oxidation rates 
are indeed normal and not compromised, and since myocardial contractility is unimpaired 
is evidence that ATP supply is sufficient to fuel contraction. Consequently, excess glucose 
uptake is neither stored nor oxidized, but is instead diverted into other glycolytic functions 
due to a modulatory effect of Pdk4. 
Currently, the role of glucose signaling independent of its energy-providing effects is largely 
unaddressed in the hypertrophic and failing heart, but has been implicated to play an 
important role in myocyte function and survival (46). Moreover, the fate of glucose is of 
interest given that increased glucose uptake and glycolysis in cardiac hypertrophy do not 
always result in concomitant increases in glucose oxidation (47-49). Our data indicate that, 
by enhancing glucose flux, cardiac LXRα activates an ancillary pathway of glycolysis, the 
HBP, increasing levels of the posttranslational modifier, O-GlcNAc. Further, we establish that 
this pathway induces transcription of natriuretic peptides via glycosylation of GATA4 and 
Mef2c, transcriptional activators of ANP and BNP (27). It is interesting that LXRα-Tg hearts 
exhibit increased basal ANP and BNP mRNA levels without inducing the complete fetal gene 
response or displaying signs of cardiac dysfunction normally associated with their induction, 
suggesting that the expression of individual fetal genes is indeed regulated by distinct signal 
mechanisms. Nevertheless, the cardioprotective effects of natriuretic peptide signaling are 
well established (25), and murine models with ablated natriuretic peptide signaling show 
increased propensity for cardiac hypertrophy and myocardial fibrosis (50-52). Therefore, 
the anti-hypertrophic and anti-fibrotic potential of local ANP and BNP signaling may largely 
contribute to the protective phenotype observed in LXRα-Tg mice, an adaptive response 
mediated via transcriptional control of glucose-O-GlcNAc-dependent signaling by cardiac 
LXRα. Future studies aimed at elucidating additional O-GlcNAc targets should provide 
further insight into the link between myocyte metabolism and survival in the diseased heart. 
In clinical cardiology, progressive cardiac remodeling often transitions into overt symptomatic 
heart failure, and although several effective treatments have been developed to prevent 
this transition, there remains a high residual risk. Alterations in myocardial substrate 
metabolism contribute to this progression, however, no metabolic modulators are part of 
the guideline-based therapy for heart failure. Promising pharmacological agents such as 
trimetazidine and perhexiline inhibit FA oxidation and indirectly cause a reciprocal shift to 
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glucose utilization, yet drugs for direct glucose enhancement are not available. Our data 
indicate that targeting LXRα as a metabolic intervention to increase glucose metabolism 
profoundly influenced cardiac hypertrophy and remodeling, independent of hemodynamic 
or neurohormonal effects.
In conclusion, this study demonstrates that LXRα confers heart-specific protective effects 
in the attenuation of pathological LV hypertrophy and preservation of cardiac function. We 
identify LXRα as an important cardiac transcriptional regulator that further promotes the 
adaptive capacity for glucose uptake and utilization in cardiac hypertrophy. Furthermore, 
this study highlights the under-recognized potential for non-energy-dependent pathways of 
glycolysis such as the HBP in promoting cytoprotection. New generation LXR agonists with 
less lipogenic profiles are currently being developed, and we postulate that such agonists 
may be useful modulators of myocyte metabolism in the prevention of pathological cardiac 
remodeling and heart failure. 
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SUPPLEMENTAL METHODS 
Experimental protocol
All experimental protocols were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals (NIH Publication No. 86-23) and with approval from the 
Institutional Animal Care and Use Committee at the University of Groningen (Groningen, 
the Netherlands). Male mice (aged 8-10 weeks) were housed on a 12hr:12hr light:dark 
cycle in a temperature-controlled environment with ad libitum access to water and chow. 
Mice were subjected to an infusion of angiotensin II (Ang II) via osmotic mini pump for 10 
days, or pressure overload by transverse aortic constriction (TAC) for either 1 or 5 weeks. 
In subsequent studies, a subset of mice underwent sham/TAC for 5 weeks for further 
assessment of myocardial FDG-glucose uptake with microPET or mitochondrial oxidative 
phosphorylation (oxphos) measurements. For all experiments, non-transgenic littermates 
(Wt) served as controls. LXRα-null mice (LXRα-/-; provided by Dr. Gustafsson) (1) and 
matching C57BL/6BomTac wild-type (WT) mice were obtained from Taconic, Denmark. 
Cardiac function was determined with echocardiography and invasive hemodynamic 
monitoring. Left ventricular (LV) tissue samples were used to perform expressional studies, 
immunohistochemical, and biochemical analyses. 
Transverse aortic constriction 
Chronic pressure overload induced via TAC is a well established model (2). Mice were 
anesthetized with 2% isoflurane/oxygen, intubated, and mechanically ventilated (MiniVent, 
Harvard Apparatus, Holliston, MA, USA). Thereafter, they were placed supine on a heated pad 
and a 0.5-1.0 cm skin incision was made to the chest. An additional small incision was made 
to access the aortic arch between the second intercostal space. The arch was constricted 
between the brachiocephalic and left carotid arteries with a 7-0 silk suture tied around 
a blunt 27-gauge needle, creating a reproducible stenosis. After ligation, the needle was 
immediately removed and the incised skin closed. Carprofen (5.0 mg/kg) was administered 
subcutaneously, perioperatively, to relieve pain. Sham procedures were identical except the 
aortic arch was not ligated.  
Subcutaneous Ang II infusion
Angiotensin II (1.0 mg/kg/day; dissolved in 0.9% NaCl) was dispensed into osmotic 
minipumps (Alzet 2004, Palo Alto, CA, USA) according to manufacturer’s instructions. Mice 
were anesthetized with 2% isoflurane/oxygen and a single dose of 3.0 mg/kg flunixin-
meglumin was given subcutaneously to alleviate wound pain. A small incision was made at 
the right flank wherein a subcutaneous pocket was prepared for pump insertion. Control 
groups received 0.9% NaCl in their pumps.
Echocardiography
In vivo cardiac dimensional and functional parameters were assessed with M-mode and 2D 
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transthoracic echocardiography (Vivid 7 equipped with 14-MHz linear array transducer; GE 
Healthcare, Chalfont St. Giles, UK) 2-3 days prior to sacrifice. Mice were anesthetized with 
2% isoflurane/oxygen, placed on a heating pad maintained at 37⁰C, followed by removal 
of chest hair via application of topical depilation agent. Parasternal short axis views were 
obtained to ensure M-mode recordings were recorded at LV mid-papillary level. From three 
cine loops, M-mode tracings were used to measure LV dimensions and fractional shortening. 
Percent fractional shortening (%FS) was calculated as: [(LVIDd-LVIDs)/LVIDd]*100; LVIDd = 
LV internal diameter in diastole, LVIDs = LV internal diameter in systole. In apical 4-chamber 
view, pulsed wave Doppler with sample volume placed at mitral valve leaflet separation was 
used to record mitral flow gradients and E and A filling velocities. 
Invasive hemodynamic measurements
In situ hemodynamics were analyzed by aortic and LV catheterization under anesthesia with 
2% isoflurane prior to sacrifice. The right carotid artery was isolated, punctured, and an 
indwelling micromanometer-tipped pressure catheter (1.4 F; Millar Instruments, Houston, 
TX, USA) was inserted. After three minutes of stabilization, arterial pressures were recorded. 
The catheter was then advanced into the LV to record intracardiac pressures. Heart rate (HR), 
aortic pressures, LV end-systolic (LVESP) and end-diastolic (LVEDP) pressures, and maximal 
and minimal first derivatives of force (dP/dtmax and dP/dtmin) were recorded. The catheter 
was then removed and the carotid artery ligated. Remaining under anesthesia, blood was 
collected via heart puncture. The thoracic cavity was then dissected and hearts were flushed 
with 10 ml phosphate-buffered saline to wash out red blood cells, then quickly excised 
and weighed. The remaining ventricle was portioned for either immunohistochemistry 
or frozen in liquid nitrogen and stored at -80⁰C until further processing for RNA, protein, 
and biochemical analyses. In a subsequent TAC cohort (n=26), 50-60 mg of fresh tissue 
was procured and stored in ice-cold preparation medium and kept on ice for oxphos 
measurements.
Histological analysis and microscopy
Mid-ventricular transverse sections were either post-fixed in 4% paraformaldehyde for 
paraffin embedding, or cryopreserved (Tissue-Tek, Sakura Finetek). Paraffin-embedded mid-
ventricular tissue were sliced into 4 µm sections and stained with the following: Massons 
trichrome for detection of collagen, FITC-labeled wheat germ agglutinin (WGA) to quantify 
myocyte cross-sectional area. Whole stained sections were scanned (Nanozoomer 2.0-HT, 
Hamamatsu, Japan), and quantification of % fibrosis of entire section was calculated at 
20X magnification (ScanScope, Aperio Technologies, Vista, CA, USA). Cardiomyocyte cross-
sectional area was measured and quantified at 20X magnification (ImageJ, NIH, Bethesda, 
MD, USA). To detect neutral lipid, 4 µm frozen LV sections were stained with hematoxylin-
eosin and Oil red O (Sigma Aldrich).
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Microarray analysis
Total RNA was extracted from LV tissue using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), 
and 2 µg of purified total RNA was used to perform whole-genome expression profiling (n=3 
per group). RNA quality was checked using the Agilent 2100 Bioanalyzer™. Samples were 
exponentially amplified from a starting amount of 50 ng to a final amount of one µg purified 
biotin-labeled cRNA using the Illumina® TotalPrep™-96 RNA Amplification Kit (Ambion, Inc., 
Austin, TX, USA). This final cRNA was evaluated and the quality, concentration, and size of 
the reaction productions were measured using the Agilent RNA 6000 Nano Kit (Agilent).
Illumina.SingleColor.MouseRef-8_V2.0 beadchips were used for microarray analysis. Chips 
were scanned using the BeadXpress Reader™ (Illumina). Beadstudio™ Illumina was used to 
import the raw data and remove any background noise. Data were converted to standard 
format and exported for use in Agilent Genespring GX™ (version 12.0, Agilent) with which 
quantile normalization of each individual well was performed. GeneTrail (http://genetrail.
bioinf.uni-sb.de/) was used to cluster differentially expressed genes into highly enriched 
functional categories according to KEGG PATHWAY analysis (http://www.genome.jp/kegg/
pathway.html).
RNA isolation and quantitative real-time PCR
Total RNA was extracted from tissue using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and 
from cells using the Nucleospin RNA II kit (Macherey-Nagel, Duren, Germany). From total 
RNA, 0.5 µg was reverse transcribed to cDNA using RNeasy Mini kit (Qiagen Inc, Valencia, 
CA, USA). The resulting cDNAs were subjected to quantitative real-time PCR using C1000 
Thermal Cycler CFX384 Real-Time PCR Detection System (Bio-Rad Laboratories, Veenendaal, 
The Netherlands). Quantification of mRNA levels were performed (Bio-Rad CFX Manager 
2.0), and transcript measurements were normalized to the invariant transcript, 36b4. 
Western blotting
Frozen LV tissue was homogenized in ice-cold lysis buffer (50 mM Tris pH 8.0, 1% NP40, 0.5% 
deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM PMSF, 15 mM Na Vanadate) supplemented 
with protease and phosphatase inhibitor cocktails (Sigma). Cells were lysed in ice-cold lysis 
buffer (50 mM Tris pH 8.0, 1% NP40, 0.5% deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM PMSF, 
2 mM EDTA) supplemented with protease inhibitor and 100 µM O-(2-acetamido-2-deoxy-D-
glucopyranosylidenamino) N-phenylcarbamate (PUGNAc) to prevent removal of O-GlcNAc 
from cellular proteins. This preparation was also used for O-GlcNAc protein determination in 
tissue lysates. Protein concentrations were measured using Bio-Rad DC Protein Assay (Bio-
Rad) for tissue, and Pierce BCA Protein Assay Kit (Thermo Scientific) for cells. Protein lysates 
(20-30 µg) were resolved on 8-15% SDS-PAGE gels, and separated proteins were transferred 
onto 0.2 µm nitrocellulose membranes (Bio-Rad). Immunoblotting was performed using 
primary and secondary antibodies from the following commercial suppliers: anti-human 
LXRα (2ZPPZ0412H, R&D Systems, Perseus Proteomics); AMPKα (#2532), phospho-AMPKα 
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(Thr172) (#2535), GLUT4 (#2213), hexokinase II (#2867), Caspase-3 (#9665) (Cell Signaling); 
anti-glucose transporter GLUT1 (ab40084, Abcam); CD36 (gift from Dr. Koonen, Groningen, 
The Netherlands); Bax (B-9) (sc-7480), Bcl-2 (C-2) (sc-7382) (Santa Cruz); O-GlcNAc CTD110.6 
(MMS-248R, Covance) supplemented where indicated with N-acetylglucosamine (GlcNAc) 
(Sigma) to demonstrate antibody specifity (Suppl. Fig. 9B); glyceraldehyde-3-phosphate 
dehydrogenase (10R-G109A, Fitzgerald, USA); rabbit anti-mouse immunoglobulins/HRP 
(P0260, Dako, Denmark); goat anti-rabbit immunoglobulins/HRP (P0448, Dako, Denmark). 
Signals were detected by ECL (PerkinElmer, Waltham, MA, USA), and densitometry was 
quantified with ImageQuant LAS 4000 (GE Healthcare Europe GmbH, Diegem, Belgium). 
Fold changes were calculated and are shown.
Biochemical assays
Myocardial lipids were extracted from 40-60 mg of LV tissue according to Bligh & Dyer 
methods (3). Commercially available kits were used to measure the following: triglycerides 
(Roche Diagnostics, Mannheim, Germany), total cholesterol and non-esterified fatty acids 
(NEFA) (DiaSys, Holzheim, Germany). Phospholipids were quantified as detailed (4). For 
measurement of myocardial glycogen, 20 mg of LV tissue was boiled in 2N HCl at 99⁰C in a 
heat block for 2 hrs with occasional vortex. Tubes were re-weighed and reconstituted with 
dH2O to original volume. Samples were neutralized with 2N NaOH. Glycogen content was 
measured using EnzyChrom Glycogen Assay Kit (BioAssay Systems, Hayward, CA, USA). 
Myocardial FDG-glucose uptake
Mice were anesthetized by inhalation of medical air and 2% isoflurane. Immediately prior to 
scan, blood glucose was sampled via tail vein bleeding (Accu-Chek Aviva; Roche Diagnostics, 
Mannheim, Germany). Small-animal PET was performed on a microPET Focus 220 system 
(Siemens, USA). Inside the camera, mice were placed on a heated pad and maintained 
under anesthesia (1.5% isolflurane). A 200 µl bolus of 18F-FDG, approximately 5 MBq, was 
administered via the penile vein. PET emission data were acquired for 30 min followed by 
a 10 min transmission scan to correct for photon attenuation and scatter. The PET images 
were reconstructed into a matrix of 512 X 512 pixels and analyzed using Inveon Research 
Workplace (Siemens, USA). Three consecutive ROIs (region of interest) were selected from 
the LV myocardium in the frontal and coronal planes. The myocardial 18F-FDG uptake was 
calculated as a standardized uptake value (SUV): SUV = mean tissue counts (Bq/ml)/[injected 
dose (Bq)/body weight (g)]. All data were corrected for time of decay (t1/2 = 
18F 109.8 min) 
before and after tracer injection.
Mitochondrial function and citrate synthase activity
Mitochondrial oxphos was measured in fresh LV tissue biopsies with pyruvate (5 mM) and 
parmitoyl-carnitine (2 mM) as substrates, each combined with malate (5 mM) and carnitine 
(5 mM). For preparation of permeabilized myocardial fibers, approximately 10-40 mg 
tissue was dissected from LV and transferred to 2 ml ice-cold preparation medium (20 mM 
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imidazole, 20 mM taurine, 0.5 mM dithiothreitol, 7.1 mM MgCl2, 50 mM MES, 5 mM ATP, 
15 mM phosphocreatine, 2.62 mM CaK2EGTA, 7.38 mM K2EGTA, pH 7.0 adjusted with KOH). 
After brief manual separation of tissue, muscle fibers were permeabilized in preparation 
medium supplemented with saponin by gentle agitation for 15 min on ice. Fibers were 
kept on ice and washed twice for 10 min by agitation in 1.5 ml washing medium (20 mM 
imidazole, 20 mM taurine, 0.5 mM dithiothreitol, 1.61 mM MgCl2, 100 mM MES, 3 mM 
KH2PO4, 2.95 mM CaK2EGTA, 7.05 mM K2EGTA, pH 7.1 adjusted with KOH), and immediately 
used for respirometric measurements. High-resolution respirometry was performed at 
37⁰C with 2.5-3.5 mg tissue biopsy using OROBOROS Oxygraph-2k (OROBOROS Instruments, 
Innsbruck, Austria). Oxygen consumption rates were measured in 1.5 ml of MiR05 buffer 
(0.5 mM EGTA, 3 mM MgCl2.6H2O, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4, 
20 mM HEPES, 110 mM sucrose, 1 g/L BSA) at 37⁰C. The O2 solubility factor of the buffer is 
0.920. Datlab Software (OROBOROS Instruments) was used for data acquisition and analysis. 
Oxygen consumption was recorded under three conditions: basal respiration rates in the 
presence of substrate alone before the addition of ADP was defined as state 2, maximal 
ADP-stimulated (4 mM) respiration rates was defined as state 3, and respiration rates in the 
absence of ADP phosphorylation and measured in the presence of oligomyocin (1 mM), an 
ATP synthase inhibitor, was termed state 4. Respiratory control ratio was calculated as the 
ratio of state 3 to state 4. Oxygen consumption rates were expressed as nmol O2/min per dry 
tissue weight (mg), and normalized to citrate synthase activity (Sigma Aldrich). 
WGA precipitation of O-GlcNAcylated proteins
Nuclear extracts were prepared from three pooled hearts using the NE-PER Nuclear and 
Cytoplasmic kit (Thermo Scientific). In brief, left ventricular tissue was minced into small 
pieces and subjected to homogenization using a Dounce homogenizer. Cytoplasmic extracts 
were obtained and stored at -20°C, and supernatant containing nuclear extracts was assayed 
to determine protein concentration (Bio-Rad). 
Precipitation of O-GlcNAcylated proteins was performed with wheat germ agglutinin (WGA)-
conjugated agarose beads, a lectin that binds to GlycNAcylated proteins (Vector Laboratories, 
Burlingame, CA, USA). The agarose WGA gel was washed twice from the stabilizing sugar 
with a bead binding buffer (20 mM Tris pH 7.4, 1 mM CaCl2, 1 mM MgCl2). Nuclear proteins 
(500 µg) were diluted 4X in bead binding buffer containing 1 µM PUGNAc. Of the diluted 
sample, 950 µl was added to 25 µl of washed agarose WGA solution, followed by overnight 
incubation at 4°C on a rocking platform. N-acetylglucosamine (GlcNAc; 20 mM), a competitor, 
was added where indicated and served as a control (Sigma). The precipitated agarose WGA-
protein complexes were obtained by centrifugation at 10,000 g for 1 min, and then washed 
three times with bead binding buffer. The complexes were then resuspended in protein 
sample buffer and boiled for 5 min. Samples were loaded on a 8% SDS polyacrylamide gel 
for electrophoresis, and Western blot was performed to identify eluted proteins using the 
following antibodies: GATA-4 (sc-25310), Nkx-2.5 (sc-14033) (Santa Cruz Biotechnology, 
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Inc.); MEF2C (#5030) (Cell Signaling). 
Neonatal rat ventricular myocyte isolation and culture
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1-3 day old Sprague-Dawley 
pups as previously described (5). Cells were cultured at 37⁰C in the presence of 5% CO2 
in Dulbecco’s Modified Eagle Medium (DMEM) containing 5% fetal calf serum (FCS) and 
penicillin-streptomycin (100 IU/ml and 100 µg/ml, respectively) (Invitrogen, Breda, The 
Netherlands). Where indicated, cells were treated for 24 hours with the following in serum-
free DMEM: 50 µM phenylephrine (PE), an α1-adrenergic receptor agonist which induces 
cellular hypertrophy (5); 100 µM 6-diazo-5-oxonorleucine (DON) (Sigma), an inhibitor of 
glutamine:fructose-6-phosphate amidotransferase (GFAT), the first and rate-limiting enzyme 
in the hexosamine biosynthesis pathway (HBP) (6); 100 µM PUGNAc (Sigma).
Adenoviral infection
Adenoviral constructs and recombinant adenovirus containing murine LXRα (Ad-LXRα) 
and LXRα-specific siRNA (si-LXRα) were produced as described previously (5). Adenoviral 
sequences used for cloning are listed in Supplemental Table 5. A GFP-expressing virus, GL2 
(Ad-cont), was used as a control (5). Cells were infected overnight at MOI of 50, unless 
otherwise indicated. After overnight incubation, cells were washed three times with PBS 
and culturing was continued in serum-free DMEM medium. Following 24 hours incubation 
in serum-free DMEM medium, the indicated treatments were administered over a 24 hour 
period.
In vitro glucose uptake assay
Glucose uptake in NRVMs was assayed using Glucose Uptake Colorimetric Assay Kit (Abcam). 
Briefly, 40x103 NRVMs were seeded per well in a 96-well plate, and cells were infected and 
treated as described above. Prior to start of assay, cells were washed three times with 
PBS and incubated in 100 µl Krebs-Ringer-Phosphate-Hepes (KRPH) solution for 40 min. 
Insulin was administered as a positive control, and was added 20 min into incubation time 
for an additional 20 min. Thereafter, 10 µl of 10 mM 2-deoxyglucose (2-DG) was added 
to each well. To assess specificity, 20-fold excess glucose (20 mM final concentration) was 
added to a control well (Suppl. Fig. 9A). After 20 min incubation, cells were washed three 
times with PBS and lysed with extraction buffer. Sample preparation was performed in 
accordance with manufacturer’s instructions, and absorbance was measured at 412 nm 
using a spectrophotometer (Benchmark Plus Microplate Reader, Bio-Rad). Fold changes, as 
compared to control cells, were calculated and are shown.
Immunofluorescence staining
Isolated cardiomyocytes were cultured in 12-well plates on 18 mm coverslips coated with 
laminin. Cells were fixed in 4% paraformaldehyde for 10 min, then permeabilized with ice-
cold 0.3% Triton X100 for 5 min. Blocking was performed in 3% bovine serum albumin (BSA) 
0.1% PBS/Tween solution containing 2% goat serum for 1 hour, followed by incubation for 
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1 hour with a monoclonal anti-human LXRα antibody (2ZPPZ0412H, R&D Systems, Perseus 
Proteomics). After washing, cells were further incubated with goat anti-mouse IgG-FITC 
secondary antibody (sc-2010, Santa Cruz, Heidelberg, Germany) and fluorescent phalloidin-
rhodamine (Invitrogen, Breda, The Netherlands) for detection of F-actin. Coverslips were 
mounted using Vectashield mounting medium with 4’,6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Burlingame, CA, USA), and imaged with a confocal microscope (Leica 
Microsystems, Wetzlar, Germany). Cell size was determined as previously described  (7).
Protein synthesis assay
NRVMs were transfected with the following adenoviruses, Ad-LXR, si-LXRα, or Ad-cont, 
for 24 hours, then cultured in serum-free DMEM medium for 24 hours. [3H]Leucine was 
administered to cells for a further 24 hours, and determination of protein incorporation is 
as previously described (5).
Statistical analysis
All data are presented as means ± standard error of the mean (SEM). Student’s paired 
2-tailed t-test was used for two group comparisons. One-way ANOVA was performed to 
analyze differences for multiple-group comparisons, followed by Bonferroni post hoc 
analysis to assess statistical significance. Kruskall-Wallis test followed by Mann-Whitney U 
test was used to analyze cell experiments (n=4-5). All results were tested at the P<0.05 level 
of significance. Statistical analyses were performed using IBM SPSS Statistics 22 software 
(Chicago, IL, USA).
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Supplemental Table 1.  Baseline Characteristics in Young and Old LXRα-Tg and Wild-type Mice
3 months 12 months
Wt LXRα-Tg Wt LXRα-Tg
Organ weight
     Body weight, g 27.2 ± 0.6 26.2 ± 0.7 40.2 ± 2.0 41.2 ± 2.2
     LV weight/tibia, mg/mm 6.3 ± 0.2 5.7 ± 0.1* 8.4 ± 0.4 7.1 ± 0.3*
     Kidney weight/tibia, mg/mm 20.7 ± 0.4 20.3 ± 0.2 30.1 ± 0.6 31.1 ± 1.1
     Liver weight/tibia, mg/mm 71.5 ± 3.1 71.9 ± 1.7 105.4 ± 5.7 113.7 ± 13.7
Echocardiography
     Interventricular septum, mm
          Diastole 0.70 ± 0.01 0.68 ± 0.01 0.71 ± 0.02 0.75 ± 0.02
          Systole 1.60 ± 0.06 1.42 ± 0.04 1.56 ± 0.08 1.47 ± 0.06
     LV posterior wall, mm
          Diastole 0.72 ± 0.01 0.70 ± 0.02 0.72 ± 0.02 0.72 ± 0.03
          Systole 1.42 ± 0.04 1.43 ± 0.05 1.44 ± 0.05 1.49 ± 0.08
    LV internal diameter, mm
          Diastole 3.77 ± 0.03 3.72 ± 0.04 3.91 ± 0.08 3.89 ± 0.11
          Systole 2.20 ± 0.03 2.14 ± 0.02 2.22 ± 0.10 2.33 ± 0.06
     Fractional shortening, % 41.7 ± 0.7 42.5 ± 0.7 43.4 ± 1.9 39.9 ± 1.2
Hemodynamics
     Heart rate, bpm 454 ± 23 479 ± 15 475 ± 15 501 ± 15
     Mean arterial pressure, mmHg 66.2 ± 2.2 66.0 ± 4.2 78.3 ± 2.3 76.9 ± 5.3
     LV end-systolic pressure, mmHg 93.8 ± 4.3 87.8 ± 3.4 106.0 ± 2.3 92.4 ± 4.2†
     LV end-diastolic pressure, mmHg 5.9 ± 1.7 5.0 ± 1.1 13.5 ± 3.0 11.3 ± 3.3
     dP/dtmax, mmHg 7999 ± 556 8596 ± 526 7217 ± 414 8154 ± 658
     dP/dtmin, mmHg -7847 ± 349 -7601 ± 582 -6111 ± 326 -6951 ± 699
Blood chemistry
     Glucose, mmol/L ‡ 12.3 ± 1.1 12.0 ± 0.8
     Triglycerides, mmol/L 0.7 ± 0.1 0.8 ± 0.1 1.7 ± 0.2 1.9 ± 0.3
     Cholesterol, mmol/L 2.0 ± 0.1 2.1 ± 0.1 2.3 ± 0.2 2.1 ± 0.1
     Non-esterified fatty acids, mmol/L 0.6 ± 0.1 0.6 ± 0.2 0.2 ± 0.03 0.3 ± 0.1
Data are expressed as means ± SEM. * P<0.05, † P<0.001, age-matched Wt versus LXRα-Tg mice. ‡ Not measured 
in 12-month mice. Wt, 3 months (n=7-15); LXRα-Tg, 3 months (n=6-15); Wt, 12 months (n=8); LXRα-Tg, 12 months 
(n=7).
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Supplemental Table 2.  Functional and Biometrical Parameters of LXRα-Tg and Wild-type Mice at Five Weeks 
Following Transverse Aortic Constriction 
Sham TAC
Wt LXRα-Tg Wt LXRα-Tg
Cardiac function (n=19) (n=22) (n=24) (n=26)
     Heart rate, bpm 411 ± 13 428 ± 17 443 ± 10 439 ± 11
     Interventricular septum, mm
          Diastole 0.72 ± 0.02 0.71 ± 0.01 1.04 ± 0.02† 0.95 ± 0.02†§
          Systole 1.37 ± 0.04 1.27 ± 0.04 1.48 ± 0.03 1.43 ± 0.04*
     LV posterior wall, mm
          Diastole 0.75 ± 0.02 0.71 ± 0.01 1.01 ± 0.02† 0.93 ± 0.02†‡
          Systole 1.44 ± 0.03 1.41 ± 0.03 1.43 ± 0.05 1.49 ± 0.03
    LV internal diameter, mm
          Diastole 4.00 ± 0.06 3.76 ± 0.05 4.00 ± 0.08 3.80 ± 0.07
          Systole 2.30 ± 0.09 2.23 ± 0.05 2.72 ± 0.09† 2.50 ± 0.06*
     LV mass/BW, mg/g 3.7 ± 0.1 3.2 ± 0.1 6.1 ± 0.2† 4.8 ± 0.2†¶
     Fractional shortening, % 40.7 ± 0.9 39.7 ± 0.8 29.8 ± 1.1† 34.1 ± 0.4†§
     Ejection fraction, % 77.6 ± 1.0 76.6 ± 0.9 63.4 ± 1.6† 69.5 ± 1.3†§
     E/A ratio 1.62 ± 0.06 1.61 ± 0.10 1.60 ± 0.06 1.62 ± 0.08
     dP/dtmax, mmHg 7761 ± 569 7586 ± 350 7777 ± 327 7514 ± 278
     dP/dtmin, mmHg -6889 ± 421 -6823 ± 421 -7732 ± 540 -6564 ± 337
Post mortem (n=21) (n=24) (n=24) (n=26)
     Body weight, g 28.7 ± 0.7 28.6 ± 0.6 28.1 ± 0.3 28.4 ± 0.4
     Heart weight/BW, mg/g 5.3 ± 0.1 4.8 ± 0.1§ 7.1 ± 0.2† 5.9 ± 0.1†¶
     Kidney weight/BW, mg/g # 16.7 ± 0.6 16.3 ± 0.4 16.5 ± 0.5 16.4 ± 0.7
     Liver weight/BW, mg/g # 52.8 ± 2.8 53.8 ± 1.5 56.4 ± 2.0 55.1 ± 1.5
Data are expressed as means ± SEM. * P<0.05, † P<0.001, TAC versus corresponding sham group; ‡ P<0.05, § 
P<0.01, ¶ P<0.001, Wt vs LXRα-Tg mice.  # n=7-8/group.
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Supplemental Figure 1
Response of cardiac LXRα overexpression in the early phase of pressure overload-induced cardiac hypertrophy. 
LXRα-Tg and Wt mice were subjected to 1 week of transverse aortic constriction (TAC). (A) Left ventricular weight to 
tibia length ratios (LV/tibia). (B) Functional determination of percent fractional shortening with echocardiography. 
Assessment of molecular determinants of (C) hypertrophy, (D-G) inflammation, and (H-I) apoptosis in the LV; 
quantitative PCR analysis of mRNA levels were normalized to 36b4; §P=0.09. (J-K) Western blot assessment of 
apoptosis markers after 1 week pressure overload: (J) Bax and Bcl2, quantified as ratio, and (K) caspase 3; protein 
normalized to GAPDH, n=6/group. Data are means ± SEM; n=7-8/group, unless otherwise indicated; *P<0.05, 
**P<0.01, ***P<0.001 versus respective sham, #P<0.05, ##P<0.01, ###P<0.001 versus Wt.
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Supplemental Figure 2
Cardiac LXRα protects against angiotensin (Ang) II stimulation. Cardiac morphometry and in vivo functional analysis 
following 10 days of Ang II (1 mg/kg/day) infusion. (A) Left ventricular weight to tibia length ratios (LV/tibia) of Wt 
and LXRα-Tg mice receiving saline (cont) or Ang II infusion via osmotic minipumps; n=6-8/cont group, n=12-14/
Ang II group. (B-C) Representative LV histological sections stained with Massons trichrome (bars = 1 mm, 100 
µm) for quantification of % fibrosis of whole heart; n=6-8/group, §P=0.07. (D) Echocardiographical assessment of 
percent fractional shortening; n=4-6/group. Hemodynamic monitoring was performed in situ to record (E) LV end-
systolic pressure (LVESP), and (F) LV end-diastolic pressure (LVEDP); n=5-9/group. Data are means ± SEM; *P<0.05, 
**P<0.01, ***P<0.001 versus respective sham, ##P<0.01 versus Wt.
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Supplemental Figure 3
Microarray analysis of left ventricular transcripts shows alterations in metabolic pathways upon myocardial 
LXRα overexpression. (A-C) Differentially expressed genes (1.2-fold, P<0.05) were classified as either up- or 
downregulated (n=3/group). Sets of genes were further clustered into functional biological pathways (KEGG 
PATHWAY analysis, FDR adjustment, P<0.0001), and major categories are shown. Gene numbers denoted are 
number of functionally annotated genes identified for highly enriched pathways per up or down classification, 
and their relative distribution within major categories are displayed as segmental percentages. (A) Differentially 
expressed genes in sham-operated LXRα-Tg versus Wt mice. (B) Genotype-specific assessment of TAC-induced 
alterations. (C) Comparative analysis of upregulated genes between Wt and LXRα-Tg mice subjected to TAC. No 
relevant categories were significantly enriched for downregulated genes.
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Supplemental Figure 4
Metabolic gene expression in the heart following 5 weeks of chronic pressure overload. (A) Key genes involved in 
glucose, and (B) fatty acid metabolism were determined to assess the impact of cardiac-specific LXRα overexpression 
at baseline and following hypertrophic perturbation. Quantitative PCR analysis of left ventricular mRNA levels 
normalized to invariant transcript, 36b4; n=6-8/group. Data are means ± SEM; *P<0.05 versus respective sham, 
#P<0.05 versus Wt.
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Supplemental Figure 5
Assessment of key metabolic proteins in substrate utilization following 5 weeks of TAC. (A-C) Protein was measured 
in the left ventricle from Western blot and expressed as fold change for the following: (A) hexokinase 2 (HK2), 
(B) phosphorylated AMPK to total AMPK, and (C) CD36. GAPDH is shown as control and for normalization in 
quantification. Data are means ± SEM; n=6-8/group; *P<0.05, **P<0.01 versus respective sham.
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Supplemental Figure 6
LXRα-deficiency impairs augmentations in glucose uptake. Assessment of myocardial 18F-FDG-glucose uptake levels 
(SUV, standard uptake value) with respect to developed left ventricular hypertrophy (LV/tibia ratio) in LXRα-/- mice 
and WT cohorts following 5 weeks of pressure overload.
Supplemental Figure 7
Effect of cardiac LXRα overexpression on mitochondrial oxidative capacity. (A, C-D) Mitochondrial oxygen 
consumption rates were measured in permeabilized LV muscle fibers from sham- and TAC-operated mice in 
the presence of (A) pyruvate, and (C) parmitoyl (C16)-carnitine (FA substrate). Data were recorded under basal 
conditions (state 2) in the presence of substrate alone, maximal ADP-stimulated respiration (state 3), and 
respiration rates with the addition of oligomyocin to inhibit ADP phosphorylation by ATP synthase (state 4); CS, 
citrate synthase. (D) Respiratory control ratios (RCR) were determined from the ratio of state 3 to 4, indicative of 
mitochondrial function. (B) Individual oxygen consumption rates were normalized to citrate synthase activity, and 
group means are displayed. Data are means ± SEM; n=6-8/group.
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Supplemental Figure 8
Altered lipid homeostasis in murine hearts overexpressing LXRα. (A) Representative LV histological sections 
of neutral lipid droplets stained with Oil Red O and hematoxylin and eosin (H&E); bar = 10 µm. Myocardial (B) 
triglyceride, and (C) phospholipid content; n=5/group. Data are means ± SEM; *P<0.05, **P<0.01 versus Wt.
Supplemental Figure 9
Modulation of glucose uptake and O-GlcNAc signaling in cardiomyocytes overexpressing LXRα. Neonatal rat 
ventricular myocytes (NRVMs) transfected with Ad-LXRα or GL2 control (Ad-cont) under basal conditions and in 
response to phenylephrine (PE) treatment for 24 hours. (A) Assessment of 2-deoxyglucose (2-DG) uptake in which 
excess glucose and insulin served as experimental controls; n=2-4/group. (B) Additional independent Western blot 
indicating Ad-LXRα- and PE-induced increases in global protein O-GlcNAcylation, which was abrogated following 
inhibition of HBP with DON. PUGNAc was administered to verify increased O-GlcNAc levels, and GAPDH served 
as loading control. Dashed line indicates where original membrane was cut prior to separate incubation with 
N-acetylglucosamine, which was used to confirm antibody specificity.
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Supplemental Table 4.   Biometrical, Echocardiographic, and Hemodynamic Parameters of LXRα-/- and Wild-type 
Mice at Five Weeks Post Transverse Aortic Constriction 
Sham TAC
WT LXRα-/- WT LXRα-/-
Post mortem (n=10) (n=8) (n=12) (n=10)
     Body weight, g 27.9 ± 0.6 25.8 ± 0.5‡ 27.3 ± 0.4 27.7 ± 0.4
     LV weight, mg 111.3 ± 2.4 100.9 ± 1.3 143.6 ± 8.6# 153.0 ± 8.5†
     Liver weight, mg 1426 ± 43 1329 ± 54 1451 ± 34 1469 ± 56
Echocardiography (n=10) (n=7) (n=12) (n=10)
     Interventricular septum, mm
          Diastole 0.73 ± 0.01 0.71 ± 0.02 0.99 ± 0.02† 1.05 ± 0.03†
          Systole 1.49 ± 0.07 1.44 ± 0.08 1.48 ± 0.05† 1.34 ± 0.09†
     LV posterior wall, mm
          Diastole 0.73 ± 0.01 0.72 ± 0.02 1.02 ± 0.03 1.04 ± 0.04
          Systole 1.34 ± 0.06 1.59 ± 0.11 1.36 ± 0.06 1.21 ± 0.05#
    LV internal diameter, mm
          Diastole 3.85 ± 0.08 3.75 ± 0.08 3.86 ± 0.13 3.84 ± 0.10
          Systole 2.24 ± 0.06 2.26 ± 0.08 2.90 ± 0.15# 3.08 ± 0.10†
     Fractional shortening, % 41.9 ± 0.6 39.8 ± 1.2 25.3 ± 1.8 19.5 ± 1.9
     E/A ratio 1.7 ± 0.1 1.6 ± 0.1 1.7 ± 0.1† 1.7 ± 0.1†
Hemodynamics (n=10) (n=7) (n=10) (n=9)
     Heart rate, bpm 482 ± 17 477 ± 25 465 ± 22 472 ± 14
     Mean arterial pressure, mmHg 72.7 ± 2.3 73.1 ± 2.8 86.6 ± 3.0# 93.1 ± 1.7†
     LV end-systolic pressure, mmHg 95.4 ± 2.5 98.1 ± 3.6 131.3 ± 3.2† 141.5 ± 5.1†
     LV end-diastolic pressure, mmHg 10.0 ± 0.9 9.2 ± 2.1 18.8 ± 1.4# 21.6 ± 1.9†
     dP/dtmax, mmHg 6995 ± 327 7757 ± 612 6279 ± 266 6751 ± 323
     dP/dtmin, mmHg -6815 ± 232 -7496 ± 608 -6089 ± 248 -6447 ± 415
     Tau, τ, msec 7.2 ± 0.2 6.8 ± 0.5 8.9 ± 0.4* 9.8 ± 0.6†
Data are expressed as means ± SEM. * P<0.05, # P<0.05, † P<0.001, TAC versus corresponding sham group; ‡ P<0.05, 
WT vs LXRα-/- mice.  
Supplemental Table 5.  Primers used for Cloning 
Gene 5’-3’
LXRα forward GTT GGATCC ACC ATGTCCTTGTGGCTGGAGG
LXRα reverse GAA CTCGAG TCA TTCGTGGACATCCCAGATC
siLXRα forward GATCCCGGAGTGTCGCCTTCGCAAATTCAAGAGATTTGCGAAGGCGACACTCCTTTTTGGAAA
siLXRα reverse AGCTTTTCCAAAAAGGAGTGTCGCCTTCGCAAATCTCTTGAATTTGCGAAGGCGACACTCCGG

